Patients with unknown hypersensitivity to Escherichia coli-derived protein, Filgrastim or its constituents. Patients with myeloid malignancy. Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond dosage regimens.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
